Skip to main content
editorial
. 2023 Sep 9;20(9):640–645. doi: 10.20892/j.issn.2095-3941.2023.0211

Figure 1.

Figure 1

A diagram summarizing CSCO guideline updates. The numbers in brackets represent the number of treatment lines recommended by the corresponding regimen. *Pembrolizumab, envafolimab, serplulimab, tislelizumab, and nivolumab + ipilimumab are preferred. &Trastuzumab + pertuzumab or trastuzumab + lapatinib are recommended.